Evasion by stealth: inefficient immune activation underlies poor T cell response and severe disease in SARS-CoV-infected mice
- PMID: 19851468
- PMCID: PMC2762542
- DOI: 10.1371/journal.ppat.1000636
Evasion by stealth: inefficient immune activation underlies poor T cell response and severe disease in SARS-CoV-infected mice
Abstract
Severe Acute Respiratory Syndrome caused substantial morbidity and mortality during the 2002-2003 epidemic. Many of the features of the human disease are duplicated in BALB/c mice infected with a mouse-adapted version of the virus (MA15), which develop respiratory disease with high morbidity and mortality. Here, we show that severe disease is correlated with slow kinetics of virus clearance and delayed activation and transit of respiratory dendritic cells (rDC) to the draining lymph nodes (DLN) with a consequent deficient virus-specific T cell response. All of these defects are corrected when mice are treated with liposomes containing clodronate, which deplete alveolar macrophages (AM). Inhibitory AMs are believed to prevent the development of immune responses to environmental antigens and allergic responses by interacting with lung dendritic cells and T cells. The inhibitory effects of AM can also be nullified if mice or AMs are pretreated with poly I:C, which directly activate AMs and rDCs through toll-like receptors 3 (TLR3). Further, adoptive transfer of activated but not resting bone marrow-derived dendritic cells (BMDC) protect mice from lethal MA15 infection. These results may be relevant for SARS in humans, which is also characterized by prolonged virus persistence and delayed development of a SARS-CoV-specific immune response in individuals with severe disease.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2762542/bin/ppat.1000636.g001.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2762542/bin/ppat.1000636.g002.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2762542/bin/ppat.1000636.g003.gif)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2762542/bin/ppat.1000636.g004.gif)
![Figure 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2762542/bin/ppat.1000636.g005.gif)
![Figure 6](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2762542/bin/ppat.1000636.g006.gif)
![Figure 7](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2762542/bin/ppat.1000636.g007.gif)
![Figure 8](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2762542/bin/ppat.1000636.g008.gif)
Similar articles
-
T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV.Antiviral Res. 2017 Jan;137:82-92. doi: 10.1016/j.antiviral.2016.11.006. Epub 2016 Nov 11. Antiviral Res. 2017. PMID: 27840203 Free PMC article. Review.
-
Molecular Basis of Coronavirus Virulence and Vaccine Development.Adv Virus Res. 2016;96:245-286. doi: 10.1016/bs.aivir.2016.08.003. Epub 2016 Aug 30. Adv Virus Res. 2016. PMID: 27712626 Free PMC article. Review.
-
Severe acute respiratory syndrome coronaviruses with mutations in the E protein are attenuated and promising vaccine candidates.J Virol. 2015 Apr;89(7):3870-87. doi: 10.1128/JVI.03566-14. Epub 2015 Jan 21. J Virol. 2015. PMID: 25609816 Free PMC article.
-
Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection.J Virol. 2014 Oct;88(19):11034-44. doi: 10.1128/JVI.01505-14. Epub 2014 Jul 23. J Virol. 2014. PMID: 25056892 Free PMC article.
-
T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice.J Virol. 2010 Sep;84(18):9318-25. doi: 10.1128/JVI.01049-10. Epub 2010 Jul 7. J Virol. 2010. PMID: 20610717 Free PMC article.
Cited by
-
Association of prior treatment with nitrogen-containing bisphosphonates on outcomes of COVID-19 positive patients.Osteoporos Int. 2024 Jan;35(1):181-187. doi: 10.1007/s00198-023-06912-6. Epub 2023 Sep 13. Osteoporos Int. 2024. PMID: 37700010
-
Immunometabolic Signature during Respiratory Viral Infection: A Potential Target for Host-Directed Therapies.Viruses. 2023 Feb 13;15(2):525. doi: 10.3390/v15020525. Viruses. 2023. PMID: 36851739 Free PMC article. Review.
-
Onodera's prognostic nutritional index: Comparison of its role in the severity and outcomes of patients with COVID‑19 during the periods of alpha, delta and omicron variant predominance.Exp Ther Med. 2022 Sep 16;24(5):675. doi: 10.3892/etm.2022.11611. eCollection 2022 Nov. Exp Ther Med. 2022. PMID: 36177343 Free PMC article.
-
Cytokine Profile of Invasive Pulmonary Aspergillosis in Severe COVID-19 and Possible Therapeutic Targets.Diagnostics (Basel). 2022 Jun 1;12(6):1364. doi: 10.3390/diagnostics12061364. Diagnostics (Basel). 2022. PMID: 35741174 Free PMC article. Review.
-
Preclinical Establishment of a Divalent Vaccine against SARS-CoV-2.Vaccines (Basel). 2022 Mar 26;10(4):516. doi: 10.3390/vaccines10040516. Vaccines (Basel). 2022. PMID: 35455265 Free PMC article.
References
-
- Lambrecht BN. Alveolar macrophage in the driver's seat. Immunity. 2006;24:366–368. - PubMed
-
- Holt PG, Strickland DH, Wikstrom ME, Jahnsen FL. Regulation of immunological homeostasis in the respiratory tract. Nat Rev Immunol. 2008;8:142–152. - PubMed
-
- Holt PG. Alveolar macrophages. IV. Interspecies differences in activity in proliferating lymphocyte cultures. Cell Immunol. 1980;50:210–215. - PubMed
-
- Jakubzick C, Tacke F, Llodra J, van Rooijen N, Randolph GJ. Modulation of dendritic cell trafficking to and from the airways. J Immunol. 2006;176:3578–3584. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous